Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pharmacyte's Diabetes treatment would have prevented this.....
http://www.usatoday.com/story/news/nation-now/2015/12/24/death-diabetes-sparks-change-new-law/77899856/
"He was young, fit, healthy. The pharmacy told him his script had expired and we're sorry, but we can't give you anymore. He tried three times to call his doctor's office and, four days later, he passed away from not having his insulin."
Fast-forward 10 months.
"I never imagined we would reach so many people with that one little story about my brother," Houdeshell said.
On Tuesday, Ohio Gov. John Kasich signed legislation passed unanimously that essentially allows pharmacists to give up to a 30-day supply of even expired prescriptions of life-sustaining drugs.
"No one should have to die because of an expired prescription and can't get hold of your doctor," said Amy and Kevin's parents, Dan and Judy Houdeshell.
The answer is MANIPULATION.
We will get our Christmas presents in early 2016.....
The question is does Pharmacyte have a better mouse trap with no side effects???
FDA approves cheaper version of top-selling diabetes drug
http://finance.yahoo.com/news/fda-approves-cheaper-version-top-215708962.html
FDA approves cheaper version of Sanofi's best-selling insulin; it's from Eli Lilly, Boehringer
Associated Press
December 16, 2015 6:18 PM
????
WASHINGTON (AP) -- Federal health officials have approved a cheaper version of the world's top-selling insulin from Sanofi for millions of U.S. patients with diabetes.
The Food and Drug Administration approved a new form of Sanofi's pen-like injector, Lantus, from drugmakers Eli Lilly and Co. and Boehringer Ingelheim.
Those companies received tentative FDA approval for their drug, called Basaglar, in August 2014. But the launch was delayed by a patent dispute with Sanofi. The three drugmakers reached an agreement in September allowing the launch of the new drug.
Insulin is a hormone that is crucial for controlling sugar levels in the blood. People with diabetes either do not produce enough insulin or cannot properly use it.
Lantus is the top product for Sanofi and the third best-selling medicine in the world by revenue. British research firm GlobalData says Lantus had sales of $12.4 billion in 2014.
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus. The most common side effects reported in company trials included allergic reactions, injection site reactions, itching, rash and weight gain.
Lilly and Boehringer already sell Basaglar in several European countries. The two companies have not set a U.S. price yet, but it likely will be significantly lower than the price for the original product.
The diabetes market is fiercely competitive, and top rivals recently have been introducing new products across several classes of diabetes pills, as well as easier-to-use insulins.
About 95 percent of the estimated 29 million Americans with diabetes have Type 2 diabetes, which is often linked to obesity and a sedentary lifestyle. Type 1 diabetes, often called insulin-dependent diabetes, typically is diagnosed in childhood or adolescence, while Type 2 diabetes typically strikes in middle age.
Rates
Thanks Peter.
Very professionally done video!!!
Unfortunately, this stock will be MANIPULATED until we get some concrete news such as cGMP or a partnership say with Diabetes.JMO
It would be beneficial if the company would provide updates to its shareholders on what is going on with the Veridis subsidiary. The company has made a significant upfront investment and represents a significant future opportunity. If nothing major is happening then we should of used the money somewhere else. JMO
Cannabis Licensing Agreement
Under the Cannabis Licensing Agreement, the Company is required to pay Austrianova an “Upfront Payment” of $2,000,000. The Company has the right to make periodic monthly partial payments of the Upfront Payment in amounts to be agreed upon between the parties prior to each such payment being made. Pursuant to a First Amendment to Licensing Agreement, the Upfront Payment due date was extended to December 31, 2015. Pursuant to a Second Amendment to Licensing Agreement, the Upfront Payment due date was extended to June 30, 2016. As of the October 31, 2015, the Company has paid Austrianova $1,400,000 of the Upfront Payment (See Notes 4 and 8).
Double the normal volume today. Does someone know something.
I bought more today....
Pharmacyte has been very quiet on its Veridis subsidiary.
Has anyone heard of what they are doing now?
TIA
Eli Lilly and Company LLY announced that it will discontinue the development of its late-stage diabetes candidate, basal insulin peglispro (BIL) that was being developed as a once-daily treatment of patients suffering from type I and type II diabetes.
The discontinuation of the development of BIL is a blow for Eli Lilly’s diabetes pipeline. We note that insulins like Novo Nordisk A/S’ NVO Tresiba and Sanofi’s SNY Toujeo are currently available in the market. Several companies are also working on bringing new and improved treatments to market.
http://finance.yahoo.com/news/eli-lilly-halts-development-basal-212509321.html
You did not answer my question on when the stock is going to 5 cents.
I want to buy at that price.
TIA
Can you give me a date so I can buy more stock?
TIA
Today is what I expected: MANIPULATION.
I have dry powder and waiting and watching.
In the end Pharmacyte will win with the science. All you have to do is look at the scientists involved. Pharmacyte has something like a large Bio/Pharma would have.
Patience is needed.
Unfortunately, this stock will be extremely manipulated for the forseeable future now that clinical trials are pushed off till 2nd qtr 2016.
It is vulnerable at this moment unless some great news comes out on diabetes.
Here is an example of two large Pharms doing a trial. Note only phase 1 and will take thru mid 2017:
Bristol-Myers Squibb and Celgene hope that adding Opdivo to that regimen could add additional months to survival, and the two companies are currently recruiting patients for a phase 1 safety study that will run until mid-2017. Although the primary goal of this study is to make sure that the combination is safe, the trial will also evaluate progression-free survival and overall survival.
Very interesting article on BMS and Celg treating Pancreatic cancer. Curious if Pharmacyte would also team with Bristol as well.
https://www.yahoo.com/
Bristol-Myers Squibb's Opdivo May Change How We Treat Pancreatic Cancer
Last year, Bristol-Myers Squibb and Celgene announced that they'll study a one-two punch combination approach in pancreatic cancer that combines Opdivo with Celgene's Abraxane, a chemotherapy drug.
Abraxane is already approved for use in metastatic pancreatic cancer patients. In clinical trials, patients receiving Abraxane and the commonly used cancer drug gemcitabine lived 1.8 months longer than patients taking gemcitabine alone.
Bristol-Myers Squibb and Celgene hope that adding Opdivo to that regimen could add additional months to survival, and the two companies are currently recruiting patients for a phase 1 safety study that will run until mid-2017. Although the primary goal of this study is to make sure that the combination is safe, the trial will also evaluate progression-free survival and overall survival.
The traders/shorts say all kinds of things.
One big one months ago was no trial was ever conducted in the US.
The other day, they said we did not get ODD from EMA.
Then you have someone doing some kind of countdown that only he knows about.
It is laughable.
Our partnership/buyout will be happen when least expected.....
Thanks for my daily chuckle. Keep it up.
Quite a bit of volume today. Covering or accumulating??
I own more than enough shares of Pharmacyte but with these prices I will be buying more. A big thank you to our MM's.
PW,
I do believe it is ours. As our ceo stated many times, they are not aware of anyone else pursuing this area.
JMO
Perhaps Australia is next for ODD.....
We can always count on your countdown. Thanks again for making me laugh.
Once again your are proven wrong. You never do your homework.
PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment
http://finance.yahoo.com/news/pharmacyte-biotech-obtains-orphan-drug-142224405.html
Promised,
It has been very quiet. I think some BIG announcements are forthcoming.
The future is bright for us longs....
I do think the ascites item is Pharmacyte. No other company is going after this.
ODD for ema is a done deal. IMO a "friendly" large bio/pharma smoothed things to make this happen. My question: what about Australia for odd pc and ascites, and US ascites????
November is diabetes month. What great timing to make an announcement.
Things should get exciting soon...
IMO, Sanofi made the wrong deal....time will tell.
Sanofi Inks $435 Million Diabetes Deal With South Korea's Hanmi
Here is a snippet from the article:
Under the agreement, Hanmi will receive an upfront payment of 400 million euros ($435 million), and is eligible for payments of up to 3.5 billion euros if it achieves certain sales and development milestones, the companies said in a statement yesterday.
Norvo was always my quiet darkhorse.
The timing of the buyout will come as a surprise to all of us...
Our time will come. Could be tomorrow, next month, early next year...all I know is the timing will be a surprise to us all ( a good surprise)
How much is Pharmacyte's Diabetes treatment worth?
Sanofi Inks $435 Million Diabetes Deal With South Korea's Hanmi
Here is a snippet from the article:
Under the agreement, Hanmi will receive an upfront payment of 400 million euros ($435 million), and is eligible for payments of up to 3.5 billion euros if it achieves certain sales and development milestones, the companies said in a statement yesterday.
As part of the pact, Sanofi will receive a worldwide license to develop and commercialize three investigational diabetes treatments, including a drug called efpeglenatide that belongs to a newer class of medicines called GLP1-agnostics that are used to control blood sugar. Hanmi will keep an exclusive option to co-commercialize the products in Korea and China.
Sanofi, France’s biggest company by market value, in October cut its forecast for sales of diabetes therapies in the next three years after sales of its best-selling Lantus insulin slumped.
http://www.bloomberg.com/news/articles/2015-11-05/sanofi-inks-435-million-diabetes-deal-with-south-korea-s-hanmi?cmpid=yhoo.headline
Looks like to me the TBD Diabetes human trials will be conducted in Europe.
May reach the market faster by going this route.
So you are telling us this will replace Celgene's gold standard?
Also note a comment from your article:
Greenberg said. "It's hard to be this optimistic without ever having treated a pancreatic cancer patient with this [therapy], but the biology of what we're doing looks so remarkably true and good."[/color]
Never treated a human being. Pharmacyte has already.....
You never do your homework......
What is on the slate for November?
1. EMA ODD approval?
2. Australian ODD approval?
3. cGMP approval?
4. NDA to FDA?
5. Viridis announcement?
6. Partnership/buyout? Cancer and or Diabetes...
Brian,
Do you know how long this can last in the human body??6 months, 1 yr ? without being replaced?
I agree with you except Pharmacyte will be bought out before ever reaching that dollar amount.
The timing of the buy-out will surprise all of us.......
and all this for a dime...unreal.....
Thanks. Very impressive diabetes background. He would not be at the consortium meeting if Pharmacyte's diabetes treatment wasn't promising.
Another W for pharmacyte......
Does anyone have more information on Prof. Dr. Hans-Peter Hammes-I googled him but it is all in German.....
Thanks Going Coastal for your easy to understand comments.
Just curious Rudy, do you think celgene would want to own 100% of Austrinova? I know I would. Not sure if this would be a stumbling block?
Thanks for great comments.
Does anyone understand the difference between Macks treatment (just approved by FDA) vs Pharmacyte's??
Here is a snippet from Mack's announcement:
ONIVYDE™ (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Is the differnce Pharmacyte targets tumors that are not growing vs Macks targets tumors that are growing??
Apparently Macks treatment has serious side effects. To me this provides Pharmacyte with a distinct advantage....
Would be nice for Pharmacyte to differentiate in future announcements...
Naughty Naughty......using such language. Your mother should wash your mouth out with soap......